NCI-2022-03215

Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer

This  phase 1 study is about testing a new treatment approach for small cell lung cancer that has come back after previous treatment. The treatment includes a drug called tazemetostat, along with two other drugs called topotecan and pembrolizumab, an immunotherapy drug. They're starting with low doses of tazemetostat and increasing it to find the best dose that works well and is safe to use. Then, they'll see how this combination of drugs affects the cancer. The goal is to find out if this treatment approach can help people with small cell lung cancer that has come back.

phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

small cell lung cancer: A type of lung cancer with small cells that grow too much and can spread to other parts of the body

immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05353439

Clinical Trial Site: Einstein

To see all available clinical trials click here.